Alfred J. Saah
Alfred J. Saah has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Alain Luxembourg
Merck & Co., Inc., Kenilworth, NJ, USA
2 shared publicationsChao Zhao
Department of Obstetrics and Gynecology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing 100044, China
2 shared publications- Christian Munk
Unit of Virus, Lifestyle and Genes, Danish Cancer Institute, Strandboulevarden 49, 2100 Copenhagen O, Denmark
2 shared publications - Christine Velicer
Epidemiology Department, Merck & Co., Inc., Rahway, NJ, USA
2 shared publications - Darron R. Brown
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana
2 shared publications - Maria Hortlund
WHO HPV LabNet Global Reference Laboratory, Dept. of Clinical Microbiology, Skåne University Hospital, Malmö and Center for Cervical Cancer Prevention, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
2 shared publications
Latest Publications
- 16 February 2026
- Published by Springer Nature
- Vol. 448, 113-127
HPV Type Replacement After HPV Vaccination
Human papillomavirus (HPV) vaccination effectively reduces the risk of HPV-attributable cancers, including cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers. Concerns for a lower-than-expected vaccine impact, as defined as an increase in the prevalence of precancer by nonvaccine types, compared to that anticipated based on attribution studies, have been raised in the postvaccination era. Three distinct and nonmutually exclusive processes—HPV type replacement, clinical unmasking, and viral unmasking—could be responsible for this apparent increase of nonvaccine types. HPV type replacement, in which nonvaccine types fill a niche left vacant after the elimination of vaccine types, is unlikely to occur due to the remarkable genetic stability of the virus and the lack of natural competition between individual HPV types. However, clinical unmasking, in which the absence of clinical interventions aimed at eliminating cervical disease caused by vaccine types permits uninterrupted progression of nonvaccine types, may occur since HPV coinfections are common. Alternatively, the observed shift could be completely erroneous due to the false discovery of type replacement via viral unmasking, a diagnostic assay artifact. In this chapter, we describe these processes and the mechanisms underlying them.
- 16 February 2026
- Published by Springer Nature
- Vol. 448, 113-127
HPV Type Replacement After HPV Vaccination
Human papillomavirus (HPV) vaccination effectively reduces the risk of HPV-attributable cancers, including cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers. Concerns for a lower-than-expected vaccine impact, as defined as an increase in the prevalence of precancer by nonvaccine types, compared to that anticipated based on attribution studies, have been raised in the postvaccination era. Three distinct and nonmutually exclusive processes—HPV type replacement, clinical unmasking, and viral unmasking—could be responsible for this apparent increase of nonvaccine types. HPV type replacement, in which nonvaccine types fill a niche left vacant after the elimination of vaccine types, is unlikely to occur due to the remarkable genetic stability of the virus and the lack of natural competition between individual HPV types. However, clinical unmasking, in which the absence of clinical interventions aimed at eliminating cervical disease caused by vaccine types permits uninterrupted progression of nonvaccine types, may occur since HPV coinfections are common. Alternatively, the observed shift could be completely erroneous due to the false discovery of type replacement via viral unmasking, a diagnostic assay artifact. In this chapter, we describe these processes and the mechanisms underlying them.
- 1 March 2021
- Published by Elsevier in The Lancet
- Vol. 397 (10279) , 1062
Control vaccine formulation – Authors' reply
- 1 March 2021
- Published by Elsevier in The Lancet
- Vol. 397 (10279) , 1062
Control vaccine formulation – Authors' reply
- Open Access
- 1 December 2020
- Published by Elsevier in Papillomavirus Research
- Vol. 10, 100202
Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
- 1 December 2020
- Published by Elsevier in Papillomavirus Research
- Vol. 10, 100202
Open AccessPrevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
- 1 May 2020
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 92, 105996
Use of real-world data for HPV vaccine trial follow-up in the Nordic region
- 1 May 2020
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 92, 105996
Use of real-world data for HPV vaccine trial follow-up in the Nordic region
- Open Access
- 1 October 2017
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 66 (3) , 339-345
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries
The long-term effectiveness of the quadrivalent human papillomavirus (qHPV) vaccine was assessed by monitoring the combined incidence of cervical intraepithelial neoplasia (CIN2, CIN3), adenocarcinoma in situ (AIS), and cervical cancer related to HPV16 or HPV18. Women from Nordic countries of Denmark, Iceland, Norway, and Sweden who received a 3-dose regimen of the qHPV vaccine in the beginning of FUTURE II (Females United to Unilaterally Reduce Endo/Ectocervical Disease; V501-015, base study NCT00092534) are followed through different national registries. Effectiveness analyses were conducted approximately 2 years following completion of the base study and occur approximately every 2 years thereafter for 10 years (ie, 14 years from day 1 of the base study). Vaccine effectiveness against HPV16/18-related CIN2 or worse (CIN2+) was estimated by comparing the observed incidence with the expected incidence of CIN2+ in an unvaccinated cohort using historical registry data. In the per-protocol population (2084 women) analysis of effectiveness after the first 12 years, there were no breakthrough cases of HPV16/18 CIN2+ after 9437 person- years of follow-up. Statistical power was sufficient to conclude that qHPV vaccine effectiveness remains above 90% for at least 10 years. The number of person-years during the follow-up interval of 10–12 years is continuing to accrue and shows a trend toward continuing effectiveness of the vaccine during that period. The qHPV vaccine shows continued protection in women through at least 10 years, with a trend for continued protection through 12 years of follow-up. NCT00092534. V501-015
- 1 October 2017
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 66 (3) , 339-345
Open AccessA 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries
The long-term effectiveness of the quadrivalent human papillomavirus (qHPV) vaccine was assessed by monitoring the combined incidence of cervical intraepithelial neoplasia (CIN2, CIN3), adenocarcinoma in situ (AIS), and cervical cancer related to HPV16 or HPV18. Women from Nordic countries of Denmark, Iceland, Norway, and Sweden who received a 3-dose regimen of the qHPV vaccine in the beginning of FUTURE II (Females United to Unilaterally Reduce Endo/Ectocervical Disease; V501-015, base study NCT00092534) are followed through different national registries. Effectiveness analyses were conducted approximately 2 years following completion of the base study and occur approximately every 2 years thereafter for 10 years (ie, 14 years from day 1 of the base study). Vaccine effectiveness against HPV16/18-related CIN2 or worse (CIN2+) was estimated by comparing the observed incidence with the expected incidence of CIN2+ in an unvaccinated cohort using historical registry data. In the per-protocol population (2084 women) analysis of effectiveness after the first 12 years, there were no breakthrough cases of HPV16/18 CIN2+ after 9437 person- years of follow-up. Statistical power was sufficient to conclude that qHPV vaccine effectiveness remains above 90% for at least 10 years. The number of person-years during the follow-up interval of 10–12 years is continuing to accrue and shows a trend toward continuing effectiveness of the vaccine during that period. The qHPV vaccine shows continued protection in women through at least 10 years, with a trend for continued protection through 12 years of follow-up. NCT00092534. V501-015
- Open Access
- 1 September 2017
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 7, 189-193
Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies
- 1 September 2017
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 7, 189-193
Open AccessIntention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies
- 8 February 2016
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 12 (7) , 00
Clarification on the Impact of Cervarix Vaccination on Human Papillomavirus Infection and Cervical Cancer in the United Kingdom
- 8 February 2016
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 12 (7) , 00
Clarification on the Impact of Cervarix Vaccination on Human Papillomavirus Infection and Cervical Cancer in the United Kingdom